DrugRisk November Januvia Update Shows Growth in Cancer-Alleging Lawsuits

DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
januvia lawsuit
DrugRisk has added studies warning of a risk of Januvia cancer.

New York, NY (PRWEB) November 27, 2013

The diabetes drug safety center at DrugRisk.com is alerting patients taking the medications Januvia or Janumet of new information on the site. Recent court records show the number of cases alleging drugs like Januvia caused pancreatic cancer have grown in November*.

DrugRisk is a free resource provided to those taking popular prescription drugs. With the latest information on product recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Januvia and Janumet are popular oral diabetes medications prescribed to those with type-2 diabetes, taken twice a day to lower blood sugar levels. In recent years, they have been the best-selling drugs for pharmaceutical company Merck**.

However, DrugRisk has added studies warning of a risk of Januvia cancer. In 2011, researchers from UCLA discovered subjects given Januvia had increased rates of pancreatic cancer and thyroid cancer***. The American Medical Association recently advised diabetes drugs like these can double the risk of pancreatitis, a major risk factor for pancreatic cancer****.

Due to the number of patients who have filed a Januvia lawsuit alleging cancer, cases have been consolidated to a special federal multidistrict litigation court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California).

Now, DrugRisk has added the latest court records from the Judicial Panel on Multidistrict Litigation, which show the number of cases filed alleging cancer from the drug class including Januvia, Byetta, Janumet or Victoza has grown to 157 in November*.

Anyone affected by cancer after taking Januvia or Janumet is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more information on the research, side effects and litigation news related to Januvia and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Judicial Panel on Multidistrict Litigation, 11/18/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-November-18-2013.pdf
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537


Contact